Latest news with #RealWorldData
Globe and Mail
25-06-2025
- Business
- Globe and Mail
OneMedNet CEO Aaron Green Issues Letter to Shareholders Highlighting Strategic Progress
MINNEAPOLIS, June 25, 2025 (GLOBE NEWSWIRE) -- OneMedNet Corporation (Nasdaq: ONMD) ('OneMedNet' or the 'Company'), a leader in AI-powered Real-World Data (RWD) announced today that Aaron Green, President and CEO, issued the following letter to shareholders and other stakeholders of the Company: Dear OneMedNet Shareholders, Partners, and Family, Following a year of significant progress, OneMedNet is navigating 2025 with strong momentum, making substantial strides in expanding our market presence, enhancing our Real-World Data platform, and developing an AI driven tool set to anonymize and De-identify data across multiple industries. My leadership team and I feel it is important that you know our key achievements, including onboarding five major data marketplaces, surpassing 121 million clinical exams in our network, and charting the path forward as we capitalize on the growing demand for de-identified data starting with regulatory-grade RWD. We are excited about OneMedNet's scalable, tech-enabled model that positions us for sustained growth and long-term value creation. 2024 Highlights AI-Powered Platform: Our federated iRWD™ platform leverages cost-effective AI tools to search, de-identify, and curate precise datasets at scale. These tools serve healthcare as well as industries like finance, telecom, and retail through advanced anonymization technology. Expanded Market Reach: We are now partnered with five leading data marketplaces—Amazon Data Exchange (AWS), Protege AI, Bayer Data Marketplace, Datavant, and HealthVerity. These platforms collectively span multiple segments of the healthcare data ecosystem, including real-world evidence, clinical trial optimization, payer-provider data exchange, and AI model training. From AWS's enterprise-scale infrastructure to Datavant and HealthVerity's leadership in de-identified health data, and Protege AI's focus on model-ready datasets, they form a powerful network supporting innovation across life sciences, pharma, and digital health. Network Growth: Our partnerships with over 1,400 hospital and healthcare provider sites have grown our medical imaging-rich RWD repository to over 121 million clinical exams, expanding organically by ~5% annually through daily patient care activities. Amplified Brand Presence: Increased participation in industry trade shows and targeted campaigns has strengthened stakeholder engagement, with imaging's role in longitudinal patient records resonating as a key differentiator. This momentum generated over 130 qualified leads—a threefold increase from previous years—demonstrating rising market interest. The growing demand for these services is further evidenced by many customers consistently returning to OneMedNet first for their data needs, driven by their positive experiences with our platform, quality data and services. Diverse Customer Base: Our healthcare regulatory-grade datasets are licensed by leading life sciences organizations for clinical trials, regulatory submissions, and AI model development, reflecting strong market validation. Regulatory Compliance: Our datasets meet stringent FDA and international standards, enabling real-world evidence (RWE) for submissions, post-market surveillance, and research. AI Innovation: We provide foundational data to train and validate AI models in medical imaging and diagnostics, accelerating advancements in precision medicine. What Sets Us Apart OneMedNet does not just collect raw data. We deliver: AI-assisted de-identification and anonymization, applicable across industries like healthcare, finance, telecom, and retail. OneMedNet delivers premium, purpose-built RWD, not raw data. Curated, regulatory-grade datasets Longitudinal tracking across multiple care events. Imaging-centric iRWD™, enhanced by custom cohort matching and AI-powered refinement. High customer satisfaction, driving repeat orders from leading life sciences organizations. The Opportunity Ahead The need for RWD has never been greater. The traditional model of running lengthy, expensive clinical trials is being disrupted. Regulators like the FDA and European Medicines Agency (EMA) are increasingly encouraging the use of RWE as part of the approval process. According to McKinsey generative AI and RWD could unlock $60 billion to $110 billion in annual value across the pharmaceutical and medical-device sectors. Recent industry analysis projects healthcare data growth at a 36% CAGR through 2030, far outpacing other sectors. OneMedNet is uniquely positioned to capture this multi-billion-dollar opportunity, leveraging our scalable platform, extensive network, and AI-driven capabilities. Subscription-Based pricing model We have added a subscription-based Data License Agreement (DLA) structure to drive Annual Recurring Revenue (ARR). Our platform now supports near real-time data updates, allowing access to curated, regulatory-grade datasets through flexible, recurring licenses. This enhances scalability, strengthens network effects, and aligns with long-term demand for high-quality RWD. Our partner hospitals and clinics share the revenue, incentivizing network expansion and data depth. Looking Forward Our three pillars—Platform, Partners, and People—anchor our strategy. Our proven AI de-identification and anonymization across industries, iRWD™ platform, growing network of provider sites, and experienced leadership team, with expertise in AI, cloud solutions, healthcare, regulatory compliance, and M&A, are aligned for execution. We are intensifying investor outreach and communication to highlight our progress and vision. To our shareholders: Thank you for your support. While stock price fluctuations may not reflect our full potential, we are building enduring value through data, scalability, and relevance to the future of healthcare and beyond. Sincerely, Aaron Green President and CEO OneMedNet Corporation Investor Relations - About OneMedNet Corporation OneMedNet is revolutionizing how the world unlocks Real-World Data (RWD), harnessing the untapped potential of over 1,400 healthcare sites through its iRWD™ platform. This isn't just data—it's the lifeblood of innovation, from de-identified medical imaging to electronic health records, fueling breakthroughs for drugmakers, medical device pioneers, and AI visionaries. With a network spanning rare diseases, oncology, cardiology, and beyond, OneMedNet delivers precision insights that redefine patient care and power the next wave of healthcare disruption. Beyond healthcare OneMedNet's proprietary AI anonymizes data for industries like finance, retail, and telecom, unlocking endless possibilities—rigorously testing production system upgrades, de-risking complex projects, and securely sharing sensitive data by stripping out personal information. Learn more at Cautionary Note Regarding Forward-Looking Statements This press release contains forward-looking statements. In addition, from time to time, we or our representatives may make forward-looking statements orally or in writing. We base these forward-looking statements on our expectations and projections about future events, which we derive from the information currently available to us. Such forward-looking statements relate to future events or our future performance, including: our financial performance and projections; our growth in revenue and earnings; and our business prospects and opportunities. You can identify forward-looking statements by those that are not historical in nature, particularly those that use terminology such as 'may,' 'should,' 'expects,' 'anticipates,' 'contemplates,' 'estimates,' 'believes,' 'plans,' 'projected,' 'predicts,' 'potential,' or 'hopes' or the negative of these or similar terms. In evaluating these forward-looking statements, you should consider various factors, including: our ability to change the direction of OneMedNet; our ability to keep pace with new technology and changing market needs; the competitive environment of our business; risks inherent with investing in Bitcoin, including Bitcoin's volatility; and our ability to implement our Bitcoin treasury strategy and its effects on our business. These and other factors may cause our actual results to differ materially from any forward-looking statement. Forward-looking statements are only predictions. The forward-looking events discussed in this press release and other statements made from time to time by us or our representatives, may not occur, and actual events and results may differ materially and are subject to risks, uncertainties, and assumptions about us. We are not obligated to publicly update or revise any forward-looking statement, whether as a result of uncertainties and assumptions, the forward-looking events discussed in this press release and other statements made from time to time by us or our representatives might not occur.
Yahoo
17-06-2025
- Health
- Yahoo
AI-Powered CDSS Enhances Patient Safety with Real-World Data
SAN FRANCISCO, June 17, 2025 /PRNewswire/ -- The growing demand for personalized medicine has accelerated the adoption of Real-World Data (RWD) in healthcare. The Tungs' Taichung MetroHarbor Hospital in Taiwan, in collaboration with AESOP Technology, conducted research on an AI-driven Clinical Decision Support System (CDSS) that leverages RWD to enable safer and more effective clinical decision-making, significantly reducing the risk of potentially inappropriate medications. The findings were published in the Journal of Medical Internet Research recently. RWD encompasses various data types, including electronic health records (EHR), insurance claims, wearable devices, environmental factors, and social determinants of health. It offers a comprehensive view of patient conditions and treatment outcomes. However, effectively utilizing RWD remains a significant challenge. As a key component of RWD, the EHR system is often constrained by the poor design of traditional CDSS. These systems frequently fire irrelevant or low-priority alerts and fail to provide specific recommendations for complex scenarios, such as off-label drug use, multimorbidity, and polypharmacy. This results in alert fatigue among physicians, causing critical alerts and reminders to be overlooked. Consequently, the completeness and accuracy of medical records are compromised, increasing the risk of inappropriate diagnoses or treatments and potentially threatening patient safety. This study addresses these challenges with an integrated AI-powered CDSS that combines MedGuard (now called RxPrime) for prescription appropriateness and DxPrime for diagnostic recommendations. By analyzing 438,558 prescriptions during a year-long trial, the system delivered 10,006 actionable recommendations, achieving a nearly 60% acceptance rate by physicians. Compared to traditional systems, this AI-enhanced approach demonstrated superior precision and practical applicability in real-world clinical settings. The results also revealed high acceptance rates in specialties such as ophthalmology (96.59%) and obstetrics/gynecology (90.01%), indicating strong applicability. In contrast, lower acceptance rates in neurology (38.54%) and hematology-oncology (10.94%) underscore the need for specialty-specific customization to address diverse clinical demands. This research highlights the transformative potential of RWD-driven AI systems with actionable recommendations to improve patient safety and support complex treatment decisions. These advancements foster greater trust and adoption of CDSS by physicians. Furthermore, by enhancing the completeness and accuracy of medical records, these systems elevate the quality of RWD, fostering a positive feedback loop that drives future medical advancements and consistently provides a reliable foundation for data-driven healthcare. About AESOP Technology AESOP Technology harnesses the power of AI to revolutionize clinical decision-making through its Clinical Diagnostic Reasoning Network model. By enhancing the accuracy of diagnoses, medication prescriptions, and medical coding, AESOP aims to improve patient safety and streamline healthcare processes. Its innovative solutions seamlessly integrate with EHR systems to boost efficiency and minimize errors, setting a new standard in medical care. View original content: SOURCE AESOP Technology Sign in to access your portfolio
Associated Press
29-01-2025
- Health
- Associated Press
StuffThatWorks Survey Reveals High Patient Interest in Participating in Clinical Trials
Data from the largest patient-reported real-world data exploration underlines new opportunities for medical research to accelerate drug development Over 93 percent of more than 6,000 respondents are interested in learning about clinical trials relevant to their condition, but unexpected barriers delay participation GAASH, Israel, Jan. 29, 2025 (GLOBE NEWSWIRE) -- StuffThatWorks, the largest, most up-to-date crowd-sourced patient-centric real-world data optimized for the medical and research community, today released the results of a new custom survey, Barriers in Clinical Trials, which shows that patients are primed to participate in clinical research1. The survey taps the reactions of over 6,000 patients with chronic conditions and reveals that an overwhelming majority of respondents consider clinical trials a path to accessing new medical treatments, with more than 93 percent interested in learning about trials that are relevant to their condition. In addition, nearly 57 percent of respondents report that they are severely impacted by their medical condition, with nearly 43 percent believing they have exhausted all other treatment options, highlighting an urgent need for additional treatment pathways. The survey's findings also reinforce the need for more proactive engagement and education; nearly 96 percent of respondents reported they received little or no information from providers about clinical trials in the last six months. 'The survey data reveal a desire among patients to access clinical trials as viable treatment options, underscoring the need for medical professionals to actively consider clinical research for addressing their patients' needs,' said Yael Elish, Founder and CEO of StuffThatWorks and a WAZE founding team member. 'This unique patient perspective and experience collected in structured form along with other organized health information provides valuable insights and underlines a new way for clinicians and researchers to engage with patients to better inform the development of study protocols to benefit patients and advance the science of medicine.' The survey was conducted among patients with chronic conditions through StuffThatWorks, the world's first large scale patient-generated Real World Data platform. StuffThatWorks empowers patients to transform their experiences and health information into structured organized Real World Data optimized for patient centric Real World Data research. Research organizations receive near real time comprehensive access to organized aggregated, de-identified data and corresponding patients. With over 3 million members across 1,250+ conditions and 1.3 billion data points in the U.S. and globally, StuffThatWorks is the largest and most up-to-date patient-generated crowd-sourced Real World Data optimized for generation of unique patient journey insights. From rare to common chronic conditions, patient insights covering various topics, including symptoms, treatments, and disease burden, can be generated in real-time and broken down by racial and ethnic demographics, geography, lifestyle, symptoms, and more. In addition to real-time access to the data set, on-demand custom surveys like this current Barriers to Clinical Trial initiative can be fielded to gain real-world insights from patients. Patients on StuffThatWorks share anonymized health information at scale on an ongoing basis. Instead of exhausting patients by re-asking mundane questions, our approach allows us to benefit from the already collected patient data and to conduct follow-up surveys for the missing information only. In addition, customers benefit from built in powerful analysis and insight generation tools that cross all conditions. 'Until now, researching the experience of people living with chronic conditions in the real world meant interviewing individual patients or running one-off limited surveys, which are time-consuming, costly, and, more importantly, limited in their ability to represent the diversity of patient populations and to provide insight beyond the limited number of questions possible,' added Elish. 'Patient crowdsourcing at scale can reveal unmatched insights on any patient-centric topic, in this case - the insights needed to address barriers to patient participation in clinical trials.' The custom survey Barriers in Clinical Trials included 6,004 respondents with an average age of 61. Patients who participated in the survey suffered from a wide range of chronic conditions, including COPD, fibromyalgia, peripheral neuropathy, tinnitus, osteoarthritis, COVID-19, multiple sclerosis, migraine, high blood pressure, and clinical depression. The study also revealed that: Most respondents (98 percent) perceive clinical trials as a path through which they can significantly benefit by being included in the development of new medical options Nearly one-third (29 percent) shared that their primary motivation for participating in clinical trials is to help advance science Almost one-quarter (23 percent) want to participate in clinical research because they have no other treatment options available For nearly one-quarter (23 percent), their physician recommended their participation in a trial, but the obstacles to involvement are travel costs and lost wages the patient would shoulder One fifth (19 percent) of respondents shared that having their medical treatment and/or receiving an honorarium would motivate them to participate in a study In addition, 41 percent shared being in a stressful or challenging financial situation, and more than 31 percent said their financials impact decision-making Only 13 percent had a doctor explain why a clinical trial could be helpful for their condition, and an overwhelming majority (nearly 96 percent) revealed they did not receive information from doctors about clinical trials in the last six months Participants indicated they are flexible regarding the possible format of clinical trials and would participate in in-person, virtual, or hybrid settings. 'The survey's data show that patients are not simply willing; they are eager to participate in clinical trials, provided they are informed and supported throughout the process,' said Chantal Beaudry, Senior Partner, Health Communications and Patient Recruitment at FINN Partners. 'This dataset provides unique, real-world perspectives invaluable to organizations seeking to engage patients more effectively and optimize their clinical trials.' FINN Partners is working with StuffThatWorks to ensure these data are shared broadly to encourage greater participation in clinical trials and accelerate the delivery of new indications and therapies to patients. Additional data from the survey is being analyzed to provide information regarding insights and barriers in specific patient populations. This comprehensive database of patient-reported outcomes is now available for custom research and real-time data analysis. These custom surveys are a new offering and can be enriched with past and future data from the comprehensive StuffThatWorks database. About StuffThatWorks Created by Waze founding team members, StuffThatWorks uses crowdsourcing and AI to transform shared patient experiences and data into the first organized large scale, multidimensional, longitudinal, real-world data set facilitating a neutral representation of diverse populations and treatments, insights generation and direct engagement with patients throughout their journey. StuffThatWorks is the home to 3M members across 1,250 condition communities that have so far shared 1.3B data points. Already the largest organized Patient Level Real World Data platform, StuffThatWorks is differentiated by its powerful data collection, structuring and organization infrastructure. The unique, proprietary data set and unique AI and powerful Chat GPT like capabilities enable the efficient generation of insights for research, market access and drug development. +1 973 818 8198
